TRCT
CVS icon

Tower Research Capital (TRC)’s CVS Health CVS Stock Holding History

Tower Research Capital (TRC)’s Portfolio CVS Stock Details CVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.73M Buy
38,067
+5,508
+17% +$424K 0.07% 277
2025
Q4 		$2.58M Buy
32,559
+11,644
+56% +$918K 0.06% 270
2025
Q3 		$1.58M Buy
20,915
+4,562
+28% +$313K 0.04% 357
2025
Q2 		$1.13M Sell
16,353
-44,303
-73% -$2.91M 0.03% 498
2025
Q1 		$4.11M Sell
60,656
-9,562
-14% -$572K 0.12% 131
2024
Q4 		$3.15M Buy
70,218
+20,107
+40% +$1.13M 0.06% 244
2024
Q3 		$3.15M Sell
50,111
-85,036
-63% -$4.96M 0.08% 171
2024
Q2 		$7.98M Buy
135,147
+116,009
+606% +$7.26M 0.13% 117
2024
Q1 		$1.53M Sell
19,138
-154,612
-89% -$11.8M 0.04% 362
2023
Q4 		$13.7M Buy
173,750
+123,116
+243% +$8.76M 0.17% 108
2023
Q3 		$3.54M Buy
50,634
+21,726
+75% +$1.54M 0.11% 164
2023
Q2 		$2M Sell
28,908
-9,918
-26% -$706K 0.07% 228
2023
Q1 		$2.88M Sell
38,826
-5,449
-12% -$457K 0.09% 141
2022
Q4 		$4.13M Sell
44,275
-86,002
-66% -$8.3M 0.17% 72
2022
Q3 		$12.4M Buy
130,277
+65,549
+101% +$6.49M 0.2% 84
2022
Q2 		$6M Sell
64,728
-93,365
-59% -$9.11M 0.13% 120
2022
Q1 		$16M Buy
158,093
+81,545
+107% +$8.57M 0.15% 117
2021
Q4 		$7.9M Buy
76,548
+47,563
+164% +$4.4M 0.14% 114
2021
Q3 		$2.46M Buy
28,985
+1,299
+5% +$109K 0.06% 214
2021
Q2 		$2.31M Sell
27,686
-107,859
-80% -$8.83M 0.06% 267
2021
Q1 		$10.2M Buy
135,545
+83,229
+159% +$6.06M 0.17% 101
2020
Q4 		$3.57M Buy
52,316
+18,311
+54% +$1.19M 0.11% 113
2020
Q3 		$1.99M Buy
34,005
+22,541
+197% +$1.4M 0.02% 395
2020
Q2 		$745K Buy
11,464
+7,643
+200% +$481K 0.03% 712
2020
Q1 		$227K Buy
+3,821
New +$255K 0.01% 693
2019
Q4 		– Sell
-20,198
Closed -$1.27M – 3670
2019
Q3 		$1.27M Sell
20,198
-2,710
-12% -$161K 0.09% 218
2019
Q2 		$1.25M Buy
22,908
+5,449
+31% +$293K 0.08% 206
2019
Q1 		$942K Sell
17,459
-37,980
-69% -$2.34M 0.06% 304
2018
Q4 		$3.63M Buy
55,439
+21,403
+63% +$1.6M 0.26% 79
2018
Q3 		$2.68M Sell
34,036
-166
-0.5% -$11.9K 0.2% 84
2018
Q2 		$2.2M Buy
34,202
+25,799
+307% +$1.7M 0.12% 149
2018
Q1 		$523K Buy
8,403
+679
+9% +$48.7K 0.04% 452
2017
Q4 		$560K Buy
+7,724
New +$562K 0.07% 265
2017
Q2 		– Sell
-100
Closed -$8K – 2825
2017
Q1 		$8K Sell
100
-13,116
-99% -$1.05M ﹤0.01% 1906
2016
Q4 		$1.04M Buy
13,216
+8,631
+188% +$698K 0.11% 197
2016
Q3 		$408K Sell
4,585
-9,636
-68% -$910K 0.04% 213
2016
Q2 		$1.36M Buy
14,221
+11,340
+394% +$1.13M 0.13% 120
2016
Q1 		$299K Buy
2,881
+2,841
+7,103% +$276K 0.04% 247
2015
Q4 		$4K Sell
40
-60
-60% -$5.88K ﹤0.01% 3170
2015
Q3 		$10K Buy
+100
New +$10.5K ﹤0.01% 2301
2015
Q2 		– Sell
-22
Closed -$2K – 4472
2015
Q1 		$2K Sell
22
-223
-91% -$22.6K ﹤0.01% 3748
2014
Q4 		$24K Sell
245
-8,359
-97% -$737K ﹤0.01% 1459
2014
Q3 		$684K Buy
8,604
+8,245
+2,297% +$650K 0.08% 200
2014
Q2 		$27K Sell
359
-8,705
-96% -$658K ﹤0.01% 1665
2014
Q1 		$678K Buy
9,064
+7,224
+393% +$510K 0.09% 168
2013
Q4 		$131K Sell
1,840
-72,317
-98% -$4.65M 0.02% 706
2013
Q3 		$4.21M Buy
+74,157
New +$4.42M 0.45% 35

Other funds holding CVS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Tower Research Capital (TRC)'s CVS Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its CVS Health (CVS) stake by 17% in Q1 2026, buying an estimated $424K and bringing the position to 38,067 shares worth $2.73M. The position accounts for 0.07% of the portfolio, ranked #277.

Tower Research Capital (TRC) first reported a position in CVS in Q3 2013 and has held it in 47 quarters since. The position peaked at $16M in Q1 2022. 1,865 funds tracked by Wall St. Rank hold CVS as of Q1 2026.

  • Tower Research Capital (TRC) held 38,067 shares of CVS Health worth $2.73M as of Q1 2026.
  • Tower Research Capital (TRC) bought 5,508 CVS Health shares in Q1 2026, an estimated $424K.
  • CVS Health made up 0.07% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #277 holding.
  • Tower Research Capital (TRC) first reported a position in CVS Health in Q3 2013 and has held it in 47 quarters since.
  • Tower Research Capital (TRC)'s CVS Health position peaked at $16M in Q1 2022.
  • 1,865 funds tracked by Wall St. Rank held CVS Health as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.